Skip to main content
MTVA
NASDAQ Life Sciences

MetaVia Hit With Nasdaq Deficiency Notice After Equity Falls Below $2.5M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.23
Mkt Cap
$8.429M
52W Low
$0.966
52W High
$13.42
52W Position info
27% above low
Off High info
91% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MTVA sits 27% above its 52-week low of $0.966.

Summary

MetaVia received a Nasdaq notice that its stockholders' equity is below the $2.5 million continued-listing minimum, with no alternative standard met. It has until January 4, 2027 to submit a compliance plan, and the likely fix is another dilutive raise.


Key Events · Legal and Risk Events · MTVA

  • Nasdaq Minimum Equity Deficiency

    Nasdaq notified MetaVia on November 17, 2026 that stockholders' equity reported in the September 30, 2026 10-Q fell below the $2.5 million required by Listing Rule 5550(b)(1), and the company does not meet the alternative compliance standards.

  • Compliance Plan Due January 4, 2027

    The company has 45 calendar days from the notice to submit a plan to regain compliance; if Nasdaq accepts it, the company may get up to 180 additional calendar days to evidence compliance.

  • Trading Continues For Now

    The notice has no immediate impact on listing — MTVA keeps trading on the Nasdaq Capital Market under its current symbol.

  • Balance Sheet Pressure Behind the Notice

    The equity shortfall follows a previously disclosed going-concern warning and $8.8M of cash that management says funds operations into 1Q 2027, making another equity raise the most likely route to compliance.


Analysis · MTVA · Life Sciences

Nasdaq has told MetaVia that its stockholders' equity has dropped below the $2.5 million minimum for continued listing, and the company does not qualify under any alternative standard. This lands on top of a going-concern warning already in the Q3 10-Q and only $8.8M of cash that management says lasts into 1Q 2027 — so the company now has to fix its balance sheet on a regulatory clock, most likely by issuing more stock. The notice itself does not halt trading, but a delisting would crush liquidity for a micro-cap biotech. The next hard date is January 4, 2027, when the compliance plan is due; Nasdaq can then extend the process by up to 180 days.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTVA was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTVA - Latest Insights

MTVA
Nov 16, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $1.23 info
Change: -$0.040 (-3%) info
Market Cap: $8.429M info
MTVA
Nov 13, 2026, 8:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.23 info
Change: -$0.170 (-12%) info
Market Cap: $8.429M info
MTVA
Nov 13, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.23 info
Change: -$0.170 (-12%) info
Market Cap: $8.429M info
MTVA
Nov 13, 2026, 8:31 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $1.23 info
Change: -$0.170 (-12%) info
Market Cap: $8.429M info
MTVA
Nov 12, 2026, 8:41 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.23 info
Change: -$0.280 (-19%) info
Market Cap: $8.429M info